ReviewCalcified tissue international2021
The Role of Bone Biopsy in the Management of CKD-MBD.
Review in Calcified tissue international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Bone Phenotype in Autosomal Dominant Polycystic Kidney Disease.Calcified tissue international · 2026Article
- Clinical approaches to osteoporosis in patients with chronic kidney disease: A comprehensive review.Endocrine journal · 2025Review
- Using Phantomless QCT for evaluating BMD evolution in maintenance hemodialysis patients.Scientific reports · 2025Article
- Evaluation of Bone Biomarkers in Renal Osteodystrophy.Life (Basel, Switzerland) · 2024Article
- Comprehensive diagnostic model for osteosarcoma classification using CT imaging features.Journal of bone oncology · 2024Article
- Vertebral fractures in patients with CKD and the general population: a call for diagnosis and action.Clinical kidney journal · 2024Review
- Ten tips on how to assess bone health in patients with chronic kidney disease.Clinical kidney journal · 2024Article
- Biochemical Clusters as Substitutes of Bone Biopsies in Kidney Transplant Patients.Calcified tissue international · 2024Article
- Evaluating Osteoporosis in Chronic Kidney Disease: Both Bone Quantity and Quality Matter.Journal of clinical medicine · 2024Review
- Mixed uremic osteodystrophy: an ill-described common bone pathology in patients with chronic kidney disease.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023Review
- Article
- Relative comparison of chronic kidney disease-mineral and bone disorder rat models.Frontiers in physiology · 2023Article
- Article
- Time for Revival of Bone Biopsy with Histomorphometric Analysis in Chronic Kidney Disease (CKD): Moving from Skepticism to Pragmatism.Nutrients · 2022Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A bone biopsy is still considered the gold standard for diagnosis of renal osteodystrophy. It allows to measure both static and dynamic parameters of bone remodeling and is the only method able to evaluate mineralization and allows analysis of both cortical and trabecular bone. Although bone volume can be measured indirectly by dual-energy X-ray absorptiometry, mineralization defects, bone metal deposits, cellular number/activity, and even turnover abnormalities are difficult to determine by techniques other than qualitative bone histomorphometry. In this review, we evaluate the role of bone biopsy in the clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.